MedPath

The ATTILA Trial: Assistive Technology and Telecare to maintain Independent Living At home for people with dementia

Not Applicable
Completed
Conditions
Mental health, neurology and aging
Mental and Behavioural Disorders
Unspecified dementia
Registration Number
ISRCTN86537017
Lead Sponsor
King's College London (UK)
Brief Summary

2013 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/24152600 protocol 2021 Other publications in https://pubmed.ncbi.nlm.nih.gov/33755548/ HTA report (added 24/03/2021) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33492349/ (added 09/08/2021)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
495
Inclusion Criteria

1. Clinical Dementia Rating of 1, 2 or 3
2. Fair access to care services (FACS) assessment indicates significant need
3. Working telephone line connected to home

Exclusion Criteria

1. Patient already receiving an ATT intervention or has previously been provided with ATT but has failed to utilise it
2. Unstable medical condition

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> There will be two co-primary outcome measures.<br><br> 1. Time in days from randomisation to institutionalisation (defined as permanent transition from living in own home to nursing or residential care home) or to an admission to acute care facility that results in permanent placement in care home.<br> 2. Cost-effectiveness of provision of assistive technology and telecare. Costs will be calculated by attaching nationally applicable unit cost measures to health and social service use and the costs of assistive technology and telecare provided<br> collected with a modified version of the Client Service Receipt Inventory (CSRI) (Beecham and Knapp 2001) for each participant at baseline, 12, 24, 52 and 104 weeks.<br><br> Data on both formal and informal caregiver inputs will be used to attach imputed values and EQ5D (EuroQoL Group 1990) and DEMQOL (Smith et al 2007) data will be used to calculate patient-specific QALYs.<br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath